Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 20/20 | 1.00 |
| ▸ | F10 | P00742 | 17/20 | 1.00 |
| ▸ | F2 | P00734 | 13/20 | 1.00 |
| ▸ | PLG | P00747 | 13/20 | 1.00 |
| ▸ | PLAU | P00749 | 13/20 | 1.00 |
| ▸ | TMPRSS6 | Q8IU80 | 4/20 | 0.75 |
| ▸ | HPN | P05981 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8187987 | 0.93 | ST14 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL8190325 | 0.90 | ST14 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL19309509 | 0.90 | ST14 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL8196584 | 0.89 | F10 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL12998731 | 0.87 | F10 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL8202516 | 0.87 | ST14 (0.90) | ST14F10F2PLGPLAU | |
| SCHEMBL8196664 | 0.86 | ST14 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL19309412 | 0.85 | ST14 (0.74) | ST14F10F2PLGPLAU | |
| SCHEMBL6874294 | 0.85 | F10 (1.00) | ST14F10F2PLGPLAU | |
| SCHEMBL29682436 | 0.85 | ST14 (1.00) | ST14F10F2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208308-B2 | Matriptase inhibitors and uses thereof against orthomyxoviridae infections | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2019-02-19 | — | — | US | disclosed |
| US-20170314023-A1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | UNIVERSITE DE SHERBROOKE (CA) | 2017-11-02 | — | — | US | disclosed |
| US-9752149-B2 | Matriptase inhibitors and uses thereof against orthomyxoviridae infections | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2017-09-05 | — | — | US | disclosed |
| US-8569313-B2 | Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2008107176-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | MMP7, DNPEP, METAP1 | ST14 12/4885F10 1148/4885F2 1287/4885 |
| US-10208308-B2 | Matriptase inhibitors and uses thereof against orthomyxoviridae infections | MMP7, MATR3, ADAMTS1 | ST14 96/4885F10 321/4885F2 995/4885 |
| US-20170314023-A1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | MMP7, MATR3, ADAMTS1 | ST14 96/4885F10 321/4885F2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.